Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

A psychologist has revealed what effect Ozempic can have on a person's sex drive and how that ties into the 'reward system'. Now, people are using Ozempic to manage their weight, but its manufacturer ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

As anti-obesity drugs gain traction and thinness is increasingly equated with health, the movement to accept diverse body ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...

Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...